Below is an excerpt from ISS ESG’s thought leadership paper “Could Stem Cells Help End the Pandemic?” The full paper is available for download from the Institutional Shareholder Services (ISS) online library.
- Stem cell therapies have advanced in recent years, particularly in the field of regenerative medicine.
- The COVID-19 pandemic triggered a race for biotechnology and pharmaceutical companies seeking applications for both treatments and a cure.
- Stem cell therapy has been proposed as a potential treatment for COVID-19 patients with severe symptoms.
- While COVID-19 vaccine/treatment stocks have been popular, investors should remain mindful of relevant ESG risks associated with proposed stem cell applications.
Ana Casilda Apacible, ISS ESG
Rey Francis Galuna, ISS ESG
Anthony Campagna, ISS EVA